Effect of YAP Inhibition on Human Leukemia HL-60 Cells. 2017

Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
Central Laboratory of Yong-chuan Hospital, Chongqing Medical University, Chongqing, 402160, China.

Background: Yes-associated protein (YAP), the nuclear effector of the Hippo pathway, is a candidate oncoprotein and participates in the progression of various malignancies. However, few reports have examined the effect of YAP inhibition in human leukemia HL-60 cells. Methods: We examined the effects of YAP knockdown or inhibition using short hairpin RNA (shRNA) or verteporfin (VP), respectively. Western blot assays were used to determine the expression levels of YAP, Survivin, cyclinD1, PARP, Bcl-2, and Bax. Cell proliferation was assessed using the cell counting kit (CCK-8) assay. Cell cycle progression and apoptosis were evaluated by flow cytometry, and apoptotic cell morphology was observed by Hoechst 33342 staining. Results: Knockdown or inhibition of YAP led to cell cycle arrest at the G0/G1 phase and increased apoptosis, inhibited cell proliferation, increased levels of Bax and cleaved PARP, and decreased levels of PARP, Bcl-2, Survivin, and cyclinD1. Moreover, Hoechst 33342 staining revealed increased cell nuclear fragmentation. Conclusion: Collectively, these results show that inhibition of YAP inhibits proliferation and induces apoptosis in HL-60 cells. Therefore, a novel treatment regime involving genetic or pharmacological inhibition of YAP could be established for acute promyelocytic leukemia.

UI MeSH Term Description Entries
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D010750 Phosphoproteins Phosphoprotein
D011166 Porphyrins A group of compounds containing the porphin structure, four pyrrole rings connected by methine bridges in a cyclic configuration to which a variety of side chains are attached. The nature of the side chain is indicated by a prefix, as uroporphyrin, hematoporphyrin, etc. The porphyrins, in combination with iron, form the heme component in biologically significant compounds such as hemoglobin and myoglobin. Porphyrin
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000077362 Verteporfin A benzoporphyrin derivative that is used in PHOTOCHEMOTHERAPY to treat wet type MACULAR DEGENERATION. 18-Ethenyl-4,4a-dihydro-3,4-bis(methoxycarbonyl)-4a,8,14,19-tetramethyl-23H,25H-benzo(b)porphine-9,13-dipropanoic acid monomethyl ester,BPD Verteporfin,BPD-MA,Benzoporphyrin Derivative Monoacid Ring A,Verteporphin,Visudyne
D000091102 YAP-Signaling Proteins Signal transducing adaptor proteins that were initially identified by their association with YES PROTO-ONCOGENE PROTEIN. They are downstream components of the HIPPO-SIGNALING PATHWAY, and act as transcriptional co-activators for TEAD TRANSCRIPTION FACTORS. YAP Intracellular Signaling Proteins,Yes-Associated Proteins,YAP Signaling Proteins,Yes Associated Proteins
D014157 Transcription Factors Endogenous substances, usually proteins, which are effective in the initiation, stimulation, or termination of the genetic transcription process. Transcription Factor,Factor, Transcription,Factors, Transcription
D015473 Leukemia, Promyelocytic, Acute An acute myeloid leukemia in which abnormal PROMYELOCYTES predominate. It is frequently associated with DISSEMINATED INTRAVASCULAR COAGULATION. Leukemia, Myeloid, Acute, M3,Leukemia, Progranulocytic,Myeloid Leukemia, Acute, M3,Progranulocytic Leukemia,Promyelocytic Leukemia, Acute,AML M3,Acute Promyelocytic Leukemia,Leukemia, Acute Promyelocytic,M3 ANLL,ANLL, M3,Acute Promyelocytic Leukemias
D015973 Gene Expression Regulation, Leukemic Any of the processes by which nuclear, cytoplasmic, or intercellular factors influence the differential control of gene action in leukemia. Leukemic Gene Expression Regulation,Regulation of Gene Expression, Leukemic,Regulation, Gene Expression, Leukemic
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis

Related Publications

Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
November 1996, Cancer letters,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
September 2002, Cancer letters,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
August 2002, Archives of pharmacal research,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
January 2007, Biopolymers,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
September 1997, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
October 1999, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
January 1997, Advances in experimental medicine and biology,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
March 1999, Zhongguo yao li xue bao = Acta pharmacologica Sinica,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
June 1982, The Journal of biological chemistry,
Min Chen, and Jian Wang, and Shi-Fei Yao, and Yi Zhao, and Lu Liu, and Lian-Wen Li, and Ting Xu, and Liu-Gen Gan, and Chun-Lan Xiao, and Zhi-Ling Shan, and Liang Zhong, and Bei-Zhong Liu
February 1995, Journal of electron microscopy,
Copied contents to your clipboard!